Substantial gaps in knowledge of Bordetella pertussis antibody and T cell epitopes relevant for natural immunity and vaccine efficacy

Human Immunology

Volumn 75, Issue 5, 2014, Pages 440-451

  Vaughan, Kerrie ^a   Seymour, Emily ^a   Peters, Bjoern ^a   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; ADENYLATE CYCLASE; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; EPITOPE; FILAMENTOUS HEMAGGLUTININ; FIMBRIAL 2; FIMBRIAL 3; GAMMA INTERFERON; HEMAGGLUTININ; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIGEN BINDING; BACTERIAL INFECTION; BORDETELLA PERTUSSIS; CHEMICAL STRUCTURE; EPITOPE MAPPING; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEDLINE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTECTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; T LYMPHOCYTE; VACCINATION; VACCINE FAILURE; WHOLE CELL; ANIMAL; CHEMISTRY; GENETICS; IMMUNITY; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; META ANALYSIS; PHYSIOLOGY; WHOOPING COUGH;

ANIMALS; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84896544610     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.02.013     Document Type: Review

References (66)

1. Holmes W.H. Whooping cough, or pertussis. Bacillary and rickettsial infections: acute and chronic, black death to white plague 1940, 395-414. Macmillan, New York. W.H. Holmes (Ed.).
2. Marconi G.P., Ross L.A., Nager A.L. A resurgence in pertussis: epidemiology and trends. Pediatr Emerg Care 2012, 28(3):215-219.
3. Committee to review adverse effects of vaccines, institute of medicine "10 Diphtheria toxoid, tetanus toxoid, and acellular pertussiscontaining vaccines". Adverse effects of vaccines: evidence and causality 2012, The National Academies Press, Washington, DC.
4. CDC: www.cdc.gov/pertussis/fast-facts.html.
5. Poland G. Pertussis outbreaks and pertussis vaccine: new insights, new concerns, new recommendations?. Vaccine 2012, 30:6957-6959.
6. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
7. Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367:1012-1019.
8. Sheridan S.L., Ware R.S., Grimwood K., Lambert S.B. Number and order of whole cell pertussis vaccines in infancy and disease protection. J Am Med Assoc 2012, 308(5):454-456.
9. Rowe J., Macaubas C., Monger T.M., Holt B.J., Harvey J., Poolman J.T., et al. Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect Immun 2000, 68:3873-3877.
10. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007, 25:391-398.
11. Mills K.H. Immunity to Bordetella pertussis. Microbes Infect 2001, 3:655-677.
12. Mooi F.R., van der Maas N.A., De Melker H.E. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect 2013, 13:1-10.
13. Octavia S., Sintchenko V., Gilbert G.L., Lawrence A., Keil A.D., Hogg G., et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis 2012, 205:1220-1224.
14. Octavia S., Maharjan R.P., Sintchenko V., Stevenson G., Reeves P.R., Gilbert G.L., et al. Insight into evolution of Bordetella pertussis from comparative genomic analysis: evidence of vaccine-driven selection. Mol Biol Evol 2011, 28:707-715.
15. Mooi F.R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 2010, 10:36-49.
16. Kurniawan J., Maharjan R.P., Chan W.F., Reeves P.R., Sintchenko V., Gilbert G.L., et al. Bordetella pertussis clones identified by multilocus variablenumber tandem-repeat analysis. Emerg Infect Dis 2010, 16:297-300.
17. Bart M.J., van Gent M., van der Heide H., Boekhorst J., Hermans P., Parkhill J., et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 2010, 11:627.
18. Mooi F.R., van Loo I.H., van G.M., He Q., Bart M.J., Heuvelman K.J., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009, 15:1206-1213.
19. Mooi F.R., van O.H., Heuvelman K., van der Heide H.G., Gaastra W., Willems R.J. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998, 66:670-675.
20. Shapiro E.D. Acellular vaccines and resurgence of pertussis. JAMA 2012, 308:2149-2150.
21. Nitsch-Osuch A., Korzeniewski K., Kuchar E., Zielonka T., Zycińska K., Wardyn K. Epidemiological and immunological reasons for pertussis vaccination in adolescents and adults. Respir Physiol Neurobiol 2013, 187(1):99-103.
22. CDC: www.cdc.gov/nchs/data/hestat/pertussis/pertussis.htm.
23. Barkoff A., Grondahl-Yli-Hannuksela K., Vuononvirta J., Mertsola J., Kallonen T., He Q. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine 2012, 30:6897-6902.
24. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988, 26(8):1595-1597.
25. Robbins J.B., Schneerson R., Trollfors B., Sato H., Sato Y., Rappuoli R., et al. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis 2005, 191(1):81-88.
26. Taranger J., et al. Mass vaccination of children with pertussis toxoid-decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001, 33:1004-1010.
27. Cherry J.D. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997, 16(Suppl. 4):S90-S96.
28. Trollfors B., Taranger J., Lagergård T., Lind L., Sundh V., Zackrisson G., et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995, 333(16):1045-1050.
29. De Magistris M.T., Romano M., Bartoloni A., Rappuoli R., Tagliabue A. Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J Exp Med 1989, 169(5):1519-1532.
30. Davies V., Vaughan K., Damle R., Peters B., Sette A. Classification of the universe of immune epitope literature: representation and knowledge gaps. PLoS One 2009, 4(11):e8084.
31. Sato H., Sato Y., Ito A., Ohishi I. Effect of monoclonal antibody to pertussis toxin on toxin activity. Infect Immun 1987, 55:909-915.
32. Olin P., Hallander H.O., Gustafsson L., Reizenstein E., Storsaeter J. Clin Infect Dis 2001, 33(Suppl. 4):S288291.
33. - regulatory T cells in lungs of mice infected with Bordetella pertussis. FEMS Immunol Med Microbiol 2012, 64:413-424.
34. Alexander F., Matheson M., Fry N.K., Labram B., Gorringe A.R. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five component acellular pertussis vaccine or to pertussis disease. Clin Vaccine Immunol 2012, 19(11):1776-1783.
35. Gorringe A.R., Ashworth L.A.E., Irons L.I., Robinson A. Effect of monoclonal antibodies on the adherence of Bordetella pertussis to Vero cells. FEMS Microbiol Lett 1985, 26:5-9.
36. Rodríguez M.E., Hellwig S.M., Pérez Vidakovics M.L., Berbers G.A., van de Winkel G.J. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol Med Microbiol 2006, 46:39-47.
37. Smith A.M., Guzmán C.A., Walker M.J. The virulence factors of Bordetella pertussis: a matter of control. FEMS Microbiol Rev 2001, 25(3):309-333.
38. Bagley K.C., Abdelwahab S.F., Tuskan R.G., Fouts T.R., Lewis G.K. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J Leukoc Biol 2002, 72(5):962-969.
39. Burns D.L. Subunit structure and enzymic activity of pertussis toxin. Microbiol Sci 1988, 5(9):285-287.
40. Carbonetti N.H. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol 2010, 5(3):455-694.
41. Poolman J.T., Hallander H.O. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 2007, 6(1):47-56.
42. van Gent M., Bart M.J., van der Heide H.G., Heuvelman K.J., Mooi F.R. Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One 2012, 7(9):e46407.
43. Maharjan R.P., Gu C., Reeves P.R., Sintchenko V., Gilbert G.L., Lan R. Genome-wide analysis of single nucleotide polymorphisms in Bordetella pertussis using comparative genomic sequencing. Res Microbiol 2008, 159(9-10):602-608.
44. Advani A., Gustafsson L., Ahrén C., Mooi F.R., Hallander H.O. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine 2011, 29(18):3438-3442.
45. Kallonen T., He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines 2009, 8(7):863-875.
46. King A.J., Berbers G., van Oirschot H.F., Hoogerhout P., Knipping K., Mooi F.R. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 2001, 147(Pt. 11):2885-2895.
47. Hijnen M., de Voer R., Mooi F.R., Schepp R., Moret E.E., van Gageldonk P., et al. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine 2007, 25(31):5902-5914.
48. He Q., Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol 2008, 3(3):329-339.
49. + lymphocytes participate in INF response to filamentous hemagglutinin from Bordetella pertussis in infants, children and adults. Clin Dev Immunol 2012, 10.1155/2012/795958.
50. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothers L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 93:1-10.
51. Di Tommaso A., Domenighini M., Bugnoli M., Tagliabue A., Rappuoli R., De Magistris M.T. Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses. Infect Immun 1991, 59:3313-3315.
52. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16:1901-1906.
53. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16:1907-1916.
54. Leef M., Elkins K.L., Barbic J., Shahin R.D. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med 2000, 191:1841-1852.
55. Mahon B.P., Sheahan B.J., Griffin F., Murphy G., Mills K.H. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med 1997, 186:1843-1851.
56. Kirimanjeswara G.S., Mann P.B., Harvill E.T. Role of antibodies in immunity to Bordetella infections. Infect Immun 2003, 71:1719-1724.
57. Mills K.H., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell- mediated immunity in protection against Bordetella pertussis. Infect Immun 1998, 66:594-602.
58. Tuomanen E.I., Zapiain L.A., Galvan P., Hewlett E.L. Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells. J Clin Microbiol 1984, 20(2):167-170.
59. Redhead K., Watkins J., Barnard A., Mills K.H. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 1993, 61:3190-3198.
60. Ryan M., Murphy G., Gothefors L., Nilsson L., Storsaeter J., Mills K.H. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 1997, 175:1246-1250.
61. + T cell immune response. PLoS One 2011, 6(3):e17271.
62. Hafler J.P., Pohl-Koppe A. The cellular immune response to Bordetella pertussis in two children with whooping cough. Eur J Med Res 1998, 3:523-526.
63. Ausiello C.M., Lande R., Urbani F., Di Carlo B., Stefanelli P., Salmaso S., et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 2000, 181:1989-1995.
64. Petersen J.W., Ibsen P.H., Haslov K., Heron I. Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis. Infect Immun 1992, 60:4563-4570.
65. Rowe J., Yerkovich S.T., Richmond P., Suriyaarachchi D., Fisher E., Feddema L., et al. Th2-Associated local reactions to the acellular Diphtheria-Tetanus-Pertussis vaccine in 4- to 6-year-old children. Infect Immun 2005, 73:8130-8135.
66. + Th1 subset. PLoS Pathog 2013, 9(1):e1003130.